Wyss InstituteBiomarker – Wyss Institute

Wyss Institute receives Massachusetts Life Science Center award to advance metabolomics and lipidomics research across Massachusetts ecosystem

Jessica Leff — Wed, 22 Jul 2026 14:03:23 +0000

By Benjamin Boettner (BOSTON) — The Wyss Institute at Harvard University has received an award from the Massachusetts Life Science Center (MLSC), enabling it to host a next-generation metabolomics and lipidomics analytical platform. The platform will allow its researchers to creatively pursue new approaches to biomarker and drug discovery across multiple health challenges the Institute is…

Source

Recapitulating intramuscular vaccination with mRNA vaccines in patient-specific Lymphoid Organ Chips

Mariel Schoen — Fri, 17 Jul 2026 13:55:40 +0000

By Benjamin Boettner (BOSTON) — The protective abilities of the Moderna and BioNTech mRNA vaccines developed against COVID-19 saved millions of lives during the pandemic and put this platform technology in the spotlight of vaccine research. By now, mRNA vaccines for other infectious diseases, such as influenza, RSV, and HIV are being tested in clinical trials and highly anticipated.

Source

The Wyss Institute’s 2026-2027 Validation Projects

Jessica Leff — Mon, 06 Jul 2026 14:00:41 +0000

Each year, the Wyss Institute’s Validation Project program identifies technologies that are ready to move beyond discovery and into the validation phase. Through dedicated funding, technical resources, business development support, market research, and engagement with clinicians, investors, industry experts, and key opinion leaders, the program helps research teams de-risk high-impact innovations…

Source

Decoding inflammatory bowel disease – on a chip

Jessica Leff — Thu, 21 May 2026 09:30:43 +0000

By Benjamin Boettner (BOSTON) — Inflammatory bowel disease (IBD), which comprises the inflammatory conditions Crohn’s disease and ulcerative colitis, affects about 1.6 million Americans, many of whom cannot be effectively treated. This is mostly due to a lack of understanding of what exactly causes the increased inflammation, fibrosis, and compromised intestinal barrier that underlie this…

Source

KeepSmilin4Abbie Foundation to drive early detection and treatment of anaphylaxis

Mariel Schoen — Mon, 11 May 2026 12:25:25 +0000

1 in 20 Americans, or almost 20 million people, are at risk of anaphylaxis. The only treatment for an anaphylactic reaction is epinephrine. A reaction may escalate quickly with symptoms that can be variable and fast moving. Tragedy strikes when epinephrine treatment is not administered early in the reaction. The death of Abbie Benford illustrates this disastrous outcome. Due to the fast…

Source

Ultrasensitive test detects biomarkers for specific form of dementia

Mariel Schoen — Tue, 05 May 2026 13:55:08 +0000

By MGB Communications (BOSTON) — Dementia affects over 57 million people worldwide, a number expected to nearly double in the next 20 years. This permanent loss of cognitive abilities affects daily function and can be caused by multiple brain pathologies, including well known ones like Alzheimer’s disease (AD). Right now, biomarkers permit diagnosis of AD but not rarer pathologies like…

Source

Wyss Institute technologies enable breakthrough in astronaut health research aboard NASA’s Artemis II mission

Jessica Leff — Thu, 09 Apr 2026 14:55:20 +0000

By Alexandra Jirstrand (BOSTON) – Launched on April 1, 2026, Artemis II is a historic, approximately 10-day lunar flyby mission that is sending four astronauts farther into space than any humans have traveled since the Apollo era, marking a critical step toward sustained lunar exploration and future missions to Mars. The Wyss Institute for Biologically Inspired Engineering at Harvard…

Source

Breaking barriers in brain health

Mariel Schoen — Wed, 18 Mar 2026 22:28:15 +0000

For decades, some of the most urgent challenges in brain health have resisted progress across both academia and the pharmaceutical industry. At the Wyss Institute, we are tackling them head-on. A central focus is overcoming one of the field’s biggest obstacles: delivering drugs effectively to the brain and central nervous system. Today, this process remains inefficient…

Source

Nucleic Acid Delivery Consortium

Mariel Schoen — Fri, 13 Mar 2026 15:13:09 +0000

Nucleic acid therapies are emerging as a revolutionary class of medicines. Using engineered DNA or RNA molecules, they treat diseases at their genetic source, thus offering potential cures for a large variety of disorders, ranging from genetic disorders to cancers and infectious diseases. Different technologies, including mRNA, short interfering RNAs (siRNA), antisense oligonucleotides (ASOs)…

Source

Tooling up to diagnose ocean health

Jessica Leff — Thu, 05 Feb 2026 14:55:24 +0000

By Benjamin Boettner (BOSTON) — Oceanic ecosystems are increasingly threatened by global warming, which causes coral bleaching, species migration, and, through the loss of habitats and biodiversity, food web disruptions on major scales. Also, pollutants such as plastics and other marine debris, wastewater, and chemical runoffs, including oil spills, cause major ecosystem disruptions.

Source